来自 40 家顶级制药公司的演讲简报（Drug Discovery Chemistry 2026）
每年都有众多业界专家登台演讲。以下是来自这 40 家公司简报的一部分。
（艾伯维(AbbVie)、安进(Amgen)、Astex Pharmaceuticals、阿斯利康(AstraZeneca)、拜耳(Bayer)、百健(Biogen)、百灵佳殷格翰(Boehringer Ingelheim)、必治妥施贵宝(Bristol Myers Squibb)、礼来(Eli Lilly)、基因泰克(Genentech)、葛兰素史克(GlaxoSmithKline)、强生(Johnson & Johnson)、默克(Merck)、诺华(Novartis)、辉瑞(Pfizer)、罗氏(Roche)、赛诺菲(Sanofi)等）
DEL-Based Identification of PTPN22 Modulators: Inhibitors, Activators, and Degraders from Distinct Allosteric Sites
Henry Korman, PhD, Senior Scientist II, Global Medicinal Chemistry, AbbVie Inc.
Targeting Tau in Neurodegenerative Disease Models: Applying Orthogonal Biophysical Approaches for PPI-Based Drug Discovery
Shaun McLoughlin, PhD, Principal Scientist I, High Throughput Screening, AbbVie Inc.
Comparing Biophysical Approaches for Lead Generation: Case Studies from Difficult Targets
Sarathy Karunan Partha, PhD, Principal Research Scientist, AbbVie Inc.
Chairperson for Emerging Technologies for Discovery Chemistry Conference
Chaohong Sun, PhD, Senior Director, Target Enabling Technologies, AbbVie, Inc.
Next-Generation Antibody Degraders: Design Principles for Tissue-Specific Receptor Degradation and ADC Payload Delivery
Felipe de Sousa e Melo, PhD, Director, Large Molecule Modality, Induced Proximity Platform, Amgen
From Membranes to Lysosomes: Rewriting Protein Fate with Small-Molecule LYMTACs
Dhanusha Nalawansha, PhD, Senior Scientist, Induced Proximity Platform, Amgen Inc.
FBDD Case Study on eIF4F-mRNA Complex: Lessons Learned
Chiara R. Valenzano, PhD, Associate Director, Molecular Science, Astex Pharmaceuticals
The Proof Is in the Pudding: Utility of Co-Folding Models in Fragment-Based Drug Discovery
Marcel Verdonk, PhD, Senior Director, Computational Chemistry & Informatics, Astex Pharmaceuticals
Higher Throughput Proteomics Screening for Degrader Target Identification and Selectivity Profiling
Anthony Iannetta, PhD, Senior Scientist, Discovery Sciences, AstraZeneca
Photocatalytic Proximity Proteomics for Mechanistic Understanding of PPIs
Jordan Mattheisen, PhD, Postdoctoral Fellow, Chemical Biology, AstraZeneca
An Industry Case Study in Mechanistic PK/PD Modeling of Covalent Degraders: Interspecies Differences, Long-Acting Injectables, and the Four Pillars
Robin Haid, PhD, Modeling & Simulation Expert, Preclinical Modeling & Simulation, Bayer AG
Designing Oral (and Permeable!) Peptides
Emel Adaligil, PhD, Executive Director, Chemical Biology and Peptide Macrocycles, Eli Lilly and Company
Enhancing Oligonucleotide Screening Efficiency with DNA-Encoded Library Technology
Dillon Flood, PhD, Scientific Director, Elsie Biotechnologies, a GSK company
Applying DEL Technology for Lead Generation across Diverse Targets: Case Studies
Benjamin Brennecke, PhD, Scientist, DELT Platform, Small Molecule Research Lead Discovery, F. Hoffmann-La Roche Ltd.
FEATURED PRESENTATION: Targeting the Hippo Pathway in Cancers
Anwesha Dey, PhD, Executive Director & Distinguished Scientist, Research Oncology, Genentech Inc.
Advances in Peptidic Conjugates with Limited Permeability: Strategies to Enhance and Validate Cellular Uptake
Jakob Fuhrmann, PhD, Senior Principal Scientist, Peptide Therapeutics, Genentech, Inc.
FEATURED PRESENTATION: Cutting and Gluing: Manipulating Protein-Protein Interactions Guided by Biophysical Insight
Mela Mulvihill, PhD, Director and Distinguished Scientist, Biochemical & Cellular Pharmacology, Genentech, Inc.
FEATURED PRESENTATION: Making Your Hits Your Early Leads: Innovative SPR Applications
John Quinn, PhD, Distinguished Scientist, Biophysical Group, Biochemical and Cellular Pharmacology, Genentech
Biophysical Methods for Encoded Oligonucleotide Hit Qualification and Development
Rajeev Chorghade, PhD, Principal Scientist, Biophysics, GlaxoSmithKline
Chairperson for DNA-Encoded Libraries Conference
Carol Mulrooney, PhD, Investigator, Cheminformatics, GlaxoSmithKline
Binding What Matters: Biophysics for Elusive Interactions
Karanbir Pahil, PhD, Senior Principal Scientist, Affinity Selections & Biophysics, GlaxoSmithKline
Prediction of Oral Bioavailability of CRBN-Based PROTACs across Various 2D and 3D Descriptors
Tong Li, PhD, Principal Scientist, In Silico Discovery, Johnson & Johnson
De novo Design of D-Peptide Ligands
Rameshwar Kadam, PhD, Senior Scientist II, Structural & Protein Sciences, Johnson & Johnson Innovative Medicine
Chairperson for Oral & Macrocyclic Peptides: Discovery to Development - Part 1 Conference
Robert D. Mazzola, PhD, Director & Principal Scientist, Chemical Research, Merck & Co.
A New Biocompatible Peptide Cyclization: Development and Application
Tianxiong Mi, PhD, Senior Scientist, Discovery Chemistry, Merck & Co.
Oral Peptide Inhibitors of IL-1b for Atherosclerotic Cardiovascular Disease
Christopher Plummer, PhD, Senior Director, Discovery Chemistry, Merck & Co
Chairperson for AI/Machine Learning for Early Drug Discovery - Part 1 Conference
Simona Cotesta, PhD, Executive Director Medicinal Chemistry, Novartis Biomedical Research
The Invisible Pathways of Innovation: AI and Automation in the New Enterprise Boom
Jose Duca, PhD, Global Head Computer Aided Drug Discovery, Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc.
Adventures in Aspartate: Covalent Targeting of KRAS G12D
Veronika Ehmke, PhD, Senior Principal Scientist, Global Discovery Chemistry, Oncology, Novartis Biomedical Research Basel
Fragment-Based Discovery Establishes Ligandability of the Transcription Factor MITF
Jürgen Hinrichs, PhD, Senior Principal Scientist, GDC Oncology, Novartis Biomedical Research
Phenotypic DEL in Droplets for TPD and Beyond
Mihaljo Todorovic, PhD, Principal Scientist II, Medicinal Chemistry, Novartis Institutes of BioMedical Research
Phenotypic DEL in Droplets for TPD and Beyond
Mihaljo Todorovic, PhD, Principal Scientist II, Medicinal Chemistry, Novartis Institutes of BioMedical Research
Understanding the Selectivity of the Molecular Glue-Induced Interactions of Zinc Finger-Based Transcription Factors with Cereblon
Charles Wartchow, PhD, Associate Director, Discovery Sciences, Novartis Institutes for BioMedical Research
Chairperson for Emerging Technologies for Discovery Chemistry Conference
Ken Yamada, PhD, Associate Director, Global Discovery Chemistry, Novartis BioMedical Research
Applying D2B to Molecular Glue Discovery
PANEL MODERATOR: Ken Yamada, PhD, Associate Director, Global Discovery Chemistry, Novartis BioMedical Research
Hit ID and Optimization Using 19F-NMR and SPR Techniques with an Orphan GPCR
Kris A. Borzilleri, Principal Scientist, Structural Biology & Molecular Sciences, Pfizer Global R&D, Groton Labs
FEATURED PRESENTATION: Trends and Learnings from Company-Wide DEL Comparisons
Timothy L. Foley, PhD, Senior Principal Scientist & Lab Head, DNA Encoded Library Selection & Pharmacology, Pfizer Global R&D Groton Labs
Tackling Hit ID in GPCR Drug Discovery with an Enhanced Toolbox Including Biophysical Approaches
Alison Heick Varghese, Principal Scientist, Pfizer Inc.
Limitations of Small Molecule and Genetic Screening in Phenotypic Drug Discovery
Fabien Vincent, PhD, Consultant; formerly Pharmacology Lab Head, Pfizer Inc.
Combining Covalent Fragment Screening, HTP Co-Crystallization, and Direct-to-Biology
Shuai Chen, PhD, Senior Scientist, Medicinal Chemistry, Roche R&D Center (China) Ltd.
* As of December 1, 2026 - Please see individual agenda pages for most up-to-date list of speakers
